Business
View from the C-Suite: Pat McCutcheon, President and CEO, MediPharm Labs Corp., tells his company's story. Filmed on October 5, 2018
View from the C-Suite: Pat McCutcheon, President and CEO, MediPharm Labs Corp., tells his ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n\n\n\nView from the C-Suite: Pat McCutcheon, President and CEO, MediPharm Labs Corp., tells his company's story. Filmed on October 5, 2018\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Nov. 9, 2018\n\n\n\nTORONTO, Nov. 9, 2018 /CNW/ - \n\n \n  \n\n \nhttps://www.youtube.com/watch?v=k8Gp5HtckDw \nThe View from the C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.  Videos provide insight into how company executives think in the current business environment.  To see the latest View from the C-Suite videos visit www.tmxmoney.com/en/news/csuite.html) \nAbout MediPharm Labs Corp. (TSXV: LABS)\nFounded in 2015, MediPharm Labs is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products.\nThrough its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug ...